Cargando…

Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality

Detalles Bibliográficos
Autores principales:	Karaboyas, Angelo, Port, Friedrich K., Massy, Ziad A., Locatelli, Francesco, Cases, Aleix, Nitta, Kosaku, Liabeuf, Sophie, Jager, Kitty J., Robinson, Bruce M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783558/ https://www.ncbi.nlm.nih.gov/pubmed/33426400 http://dx.doi.org/10.1016/j.ekir.2020.10.003

Ejemplares similares

The association between longer haemodialysis treatment times and hospitalization and mortality after the two-day break in individuals receiving three times a week haemodialysis
por: Fotheringham, James, et al.
Publicado: (2019)

Association between allopurinol and mortality among Japanese hemodialysis patients: results from the DOPPS
por: Tsuruta, Yuki, et al.
Publicado: (2014)

From old uraemic toxins to new uraemic toxins: place of ‘omics’
por: Massy, Ziad A, et al.
Publicado: (2018)

Will There Be a Role for a Short-Acting Biosimilar Erythropoiesis-Stimulating Agent in US Nephrology Practice?
por: Wish, Jay B.
Publicado: (2019)

Beta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study
por: Kanda, Eiichiro, et al.
Publicado: (2020)

Does kidney transplantation influence a form of discrimination for antihypertensive drugs prescriptions?
por: Cheddani, Lynda, et al.
Publicado: (2021)

Changes in clinical indicators related to the transition from dialysis to kidney transplantation—data from the ERA-EDTA Registry
por: Tantiyavarong, Pichaya, et al.
Publicado: (2019)

Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation
por: Liabeuf, Sophie, et al.
Publicado: (2018)

Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?
por: El Chamieh, Carolla, et al.
Publicado: (2022)

Protein-Bound Uremic Toxins: New Insight from Clinical Studies
por: Liabeuf, Sophie, et al.
Publicado: (2011)

Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
por: Bernieh, Bassam, et al.
Publicado: (2014)

Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
por: Karaboyas, Angelo, et al.
Publicado: (2020)

Hyperkalemia excursions are associated with an increased risk of mortality and hospitalizations in hemodialysis patients
por: Karaboyas, Angelo, et al.
Publicado: (2020)

Mortality risk in patients on hemodiafiltration versus hemodialysis: a ‘real-world’ comparison from the DOPPS
por: Locatelli, Francesco, et al.
Publicado: (2018)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Understanding associations of hemodialysis practices with clinical and patient-reported outcomes: examples from the DOPPS
por: Port, Friedrich K., et al.
Publicado: (2017)

Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients
por: Lenglet, Aurélie, et al.
Publicado: (2013)

Comparison of homocitrulline and carbamylated albumin as biomarkers of carbamylation reactions in hemodialyzed patients
por: Lenglet, Aurelie, et al.
Publicado: (2023)

A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders
por: Das, Monojit, et al.
Publicado: (2022)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

The Addition of Vascular Calcification Scores to Traditional Risk Factors Improves Cardiovascular Risk Assessment in Patients with Chronic Kidney Disease
por: Liabeuf, Sophie, et al.
Publicado: (2015)

Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins
por: Laville, Solène M., et al.
Publicado: (2021)

Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study
por: Karaboyas, Angelo, et al.
Publicado: (2018)

International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes and Practice Patterns Study
por: Chan, Kevin, et al.
Publicado: (2019)

Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry
por: Jansz, Thijs T, et al.
Publicado: (2019)

Association between Free Light Chain Levels, and Disease Progression and Mortality in Chronic Kidney Disease
por: Desjardins, Lucie, et al.
Publicado: (2013)

Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD
por: Massy, Ziad A., et al.
Publicado: (2019)

Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa
por: Tani, Junya, et al.
Publicado: (2020)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review
por: Bruce, Gordon, et al.
Publicado: (2022)

Uremic Toxins and Vascular Dysfunction
por: Six, Isabelle, et al.
Publicado: (2020)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Estimating the Fraction of First-Year Hemodialysis Deaths Attributable to Potentially Modifiable Risk Factors: Results from the DOPPS
por: Karaboyas, Angelo, et al.
Publicado: (2020)

Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
por: Portolés, Jose, et al.
Publicado: (2021)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
por: Yan, X, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v2l00tdouik4kshqh0eim232nm